Potentiation by naloxone of the anti-oxotremorine effect of L-DOPA.
Pretreatment with the catecholamine precursor L-DOPA but not the narcotic antagonist naloxone suppressed the tremorigenic effect of oxotremorine in mice. However, when animals were pretreated with both L-DOPA and several different doses of naloxone, there was a dose-related potentiation of the antitremor effect of L-DOPA. Naloxone also produced dose-dependent potentiation of the antitremor activity of lower doses of L-DOPA in the presence of the peripheral decarboxylase inhibitor carbidopa. These findings suggest a possible therapeutic application for naloxone in treatment of dopamine dysfunction disorders.
D000818:Animals; D002230:Carbidopa / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D007980:Levodopa / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009270:Naloxone / Q000494:pharmacology*; D010095:Oxotremorine / Q000037:antagonists & inhibitors*; D014202:Tremor / Q000139:chemically induced / Q000517:prevention & control*
D009270:Naloxone; D007980:Levodopa; D010095:Oxotremorine; D002230:Carbidopa